PPARG and type 2 diabetes mellitus: Valsartan and Telmisartan were tested in type II diabetes with immune effects, perhaps binding to Peroxisome Proliferator-Activated Receptor Gamma (PPAR-γ) [17], and Valsartan is able to slow down the progression of chronic kidney disease [18].